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PrEv5t, R., and Horst. W. (1952) . Strahlentherapie, 88, 253. Quimby. E. H.. and Werner. S. C. (1949) . J. Amer. med. Ass., 140, 1046 . Roberts, G. F. (1948 . Lancet, 1. 65. Schmidt, C E.. and Nadelhaft, J. (1953) . Lab Werner, S. C., Hamilton, H., and Nemeth, M. R. (1952 A relatively stable waterin-oil emulsion prepared by using an emulsifier known as " arlacel " and a mineral oil (" bayol F ") was introduced by Freund et al. (1948a Freund et al. ( , 1948b , and this was found by Salk and Laurent (1952) to be relatively free from undesirable side-effects. Salk et al. (1952) used an influenza virus vaccine to which arlacel and bayol F had been added, and confirmed the adjuvant effect which these materials produced in man. They found that the antibody response was enhanced in amount so that the titre of serum antibodies after use of one-tenth the normal amount of antigen in an adjuvant menstruum was greater than that produced by the full amount of antigen in a saline medium. The antibody response was also prolonged in duration, and twelve months after inoculation the level had fallen only slightly from the peak titre. Salk further stated (1953) bodies to be formed against a related yet distinct antigenic type of virus A as well as against the homologous antigen.
These reports led the Medical Research Council's Committee on Clinical Trials of Influenza Vaccine to explore the use of oil adjuvant influenza vaccines in this country. It was decided first to compare the serological response to a single (monovalent) influenza A vaccine in saline to which aluminium phosphate had been added with that found when the vaccine was suspended as a water-in-oil emulsion. A supply of purified arlacel and of a mineral oil was obtained through the courtesy of Dr. Salk. The Liverpool strain of influenza virus A (A /Eng/ 1 / 51) was selected as suitable for use partly because this strain had been used with apparent success in earlier trials in Great Britain and partly because egg-and mouse-adapted lines or substrains were available.
Since the previous report of this Committee (1953) evidence has been obtained in the laboratory that mouseadaptation of an influenza virus appears to confer an improved antigenicity upon the strain when the latter is compared with the same virus passaged only in eggs. This was first shown to be true by immunization experiments in mice (Isaacs and Sampaio, 1953) , and later the serological response in man to a mouse-adapted virus (Liverpool, A/Eng/ 1/51) was compared with that exhibited to the egg-adapted line of the same strain. Table I shows the geometrical mean titre of serum anti- bodies in 57 men before and after inoculation subcutaneously with an egg-virus vaccine suspended in saline and similar titres in a further 78 men receiving a mouseadapted virus vaccine containing the same concentration of virus. The antibody response to the latter virus appeared to be superior to that produced by the egg virus, as determined by the haemagglutination-inhibition test. These previously unpublished experiments reported to the Committee in 1953 suggested that a further trial comparing mouse-and egg-virus vaccines made from the same strain but to which oil adjuvants had been added would give useful additional information. It was therefore decided to use the mouse-adapted line of the Liverpool strain of virus A both in a saline and in an oily medium, and to use the egg strain in an oily medium only. This study was designed to test the antibody response to these three vaccines and to obtain information upon the local and general reactions consequent upon their inoculation. Holt's method (1950) by mixing equimolar solutions of AlCl3.6H20 and Na3PO4.12H20. The resultant precipitate was washed in neutral M/10 phosphate buffer solution before being added to the virus suspension in saline.
Merthiolate was added to each of the vaccines to give a final concentration of 1:10,000 in the aqueous phase.
General Reactions General reactions characterized by headache, either alone or accompanied by such symptoms as lassitude, malaise, sweating, giddiness, nausea, and so on, were experienced in relatively few instances. Table II shows the incidence after Chronic induration was still present at three months in 10, 2, and 2 volunteers receiving vaccines C, A, and B respectively, at six months in 8, 2, and 1, and at one year in 4, 2, and 0. At this time, one year from inoculation, the indurations were less than 1 cm. in diameter, and were more or less sharply defined. One (C) had disappeared and the other had declined in size still further when the arms were inspected fifteen months from the time of inoculation.
Comparison between the indurations noted in the three groups of volunteers must take into account the fact that the saline vaccine C was given subcutaneously, whereas the oily vaccines were inoculated intramuscularly, so that reactions to the latter inocula were less accessible to palpation.
Two volunteers, one given vaccine A and one vaccine B, had reactions which appear worthy of detailed description. The first case was that of a volunteer given vaccine A in whom some swelling and induration were found immediately after inoculation; nothing was again noted until one year later, when the whole of one insertion of the triceps was discovered to be very slightly and painlessly thickened. Three months later a short band of thickened fibrous tissue in the triceps (approximately 50-60 mm. by 1-2 mm.) was still present. There was some doubt about whether this had any relation to the inoculation, but, in view of its site and in the absence of any other explanation of its presence, it was so recorded. The case is not included in those with induration at one year, though it was included in the early stage referred to.
The second case was that of a volunteer who had received vaccine B and exhibited a local reaction from the start. At three months it was in the form of a hard swelling, diffuse and ill-defined, which seemed to involve the greater part of one head of the triceps. It was estimated to be about 5 cm. in diameter. At six months it had decreased to 3 cm., and at one year and again three months later there was little to note except that the muscle generally was slightly firmer than normal.
These two reactions were the only instances of possible abscess in those receiving oily vaccines, and neither led to liquefaction or cyst formation such as were described by Philip et al. (1954) (b) The mean antibody titre remained elevated above the initial titre for at least one year after inoculation with each vaccine. The mean titre in those given vaccine C was still about five times the initial level, while the corresponding figures for A and B were approximately eleven and seven times. The fall in antibodies in those receiving the oil adjuvant vaccines was, however, greater at one year than had been expected.
(c) The egg-adapted virus strain used in vaccine B was not so effective an antigen as the mouse-adapted strain used in vaccine A.
(d) In one centre (Sheffield) a number of sera obtained both before and at intervals after vaccination were titrated with a heterologous influenza virus A strain. The latter was the A/Eng/ 1/54 recovered from a small localized outbreak of influenza at a hospital in Essex in 1954. The results obtained with homologous virus and with the heterologous virus, which was a line passaged only in eggs, showed that the antibody responses in nine volunteers given the saline mouse vaccine (C) were insignificant as measured by the heterologous virus except in two instances. Similar insignificant responses were found in three volunteers given the oily (mouse) vaccine (A) whose sera were tested against the heterologous strain. Of nine volunteers inoculated with the oily (egg) vaccine (B) and exhibiting good homologous antibody responses five gave relatively good heterologous responses. These few observations indicate that oil adjuvant vaccines cannot be relied upon to increase the breadth of antibody response to heterologous virus A strains. 5-4 11-9 10 9 7-2 C 9-4 9-2 7-9 6-4 4-9 MEDImi-. ITJ.l-t vaccine was, moreover, matched against the best saline vaccine from the standpoint of antigenic content which could be made, and its superiority was thereby abundantly demonstrated.
Discussion
Salk's observations concerning the breadth of antibody response could not, however, be substantiated so far as one other virus A strain was concerned. Use of adjuvants in influenza vaccines is probably not, therefore, a solution to the problem of the immunological specificity of the inactivated influenza virus vaccine.
The rate of reactions recorded in this trial was considered to be satisfactory and to be low enough to permit exploration of a field trial using oily vaccines. At the same time, the occasional chronic reaction, often discovered only on clinical examination and not causing any grave inconvenience, appears likely to be encountered, but even the alumcontaining saline vaccine is not free from such chronic effects.
The antibody response to the emulsified vaccines appears relatively less persistent than had been anticipated. This may have been due to a deficiency of the adjuvant principle contained in the emulsions which were used. The arlacel provided by Dr. S5lk was of exceptional purity, but the efficiency of emulsions may be related in part to the content of impurities in the emulsifier. It is therefore possible that an emulsion containing more of these impurities might give a more durable antibody response. The reaction rate with such preparations might, however, be greater than with purer and therefore more easily assimilated materials. More work is clearly desirable on this and other matters connected with adjuvant vaccines.
The comparison of the antibody titres obtained with eggand mouse-adapted virus vaccines favours the latter. It is, however, difficult to be sure of the significance of the higher antibody levels with mouse-adapted virus. The differences with the two lines are not so striking as in experiments with mice. Since a number of factors such as small antigenic differences and differences in the avidity for antibody may be concerned, it seems wisest to delay interpreting these results and to compare instead the protective value of the two lines of virus. The results of trials of this nature are awaited at the moment. 1952 -3 (Report, 1953 . In these trials the attack rate of clinical influenza was 3% in 6,340 volunteers who received the virus vaccine and 4.9 % in 6,370 who received a control bacterial vaccine. It therefore seemed clear that the vaccine had a protective effect. The method of diagnosis used in these trials was entirely clinical, unaided by laboratory tests. The Committee chose the method deliberately because of the practical difficulty in obtaining and testing blood samples and throat washings from sick volunteers in trial centres scattered throughout the United Kingdom, and because it was doubted whether serological methods were valid for comparing the influenza attack rates in two groups of persons, one of which had been vaccinated with influenza virus. The Committee agreed that a small-scale trial using the same vaccines should be carried out simultaneously within the main scheme to study the practicability of basing diagnoses on both clinical and laboratory methods, and to compare results of serological tests in the vaccinated and control groups. This report describes a trial carried out in Vauxhall Motor Works, Luton, with these aims in view.
Organization of the Trial Early in October, 1952, the firm was asked whether facilities could be given for an influenza vaccine trial which would include the home visiting of the vaccinated volunteers when they were away from work, and the taking of specimens where indicated for laboratory examination. The management and chief medical officer agreed, but thought that the works council, representing the employees, should be consulted about the home inquiry. The 
